Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 165

1.

Endothelial-specific deficiency of megalin in the brain protects mice against high-fat diet challenge.

Bartolome F, Antequera D, de la Cueva M, Rubio-Fernandez M, Castro N, Pascual C, Camins A, Carro E.

J Neuroinflammation. 2020 Jan 14;17(1):22. doi: 10.1186/s12974-020-1702-2.

2.

Role of c-Jun N-Terminal Kinases (JNKs) in Epilepsy and Metabolic Cognitive Impairment.

Busquets O, Ettcheto M, Cano A, R Manzine P, Sánchez-Lopez E, Espinosa-Jiménez T, Verdaguer E, Dario Castro-Torres R, Beas-Zarate C, X Sureda F, Olloquequi J, Auladell C, Folch J, Camins A.

Int J Mol Sci. 2019 Dec 30;21(1). pii: E255. doi: 10.3390/ijms21010255. Review.

3.

Epigallocatechin-3-Gallate (EGCG) Improves Cognitive Deficits Aggravated by an Obesogenic Diet Through Modulation of Unfolded Protein Response in APPswe/PS1dE9 Mice.

Ettcheto M, Cano A, Manzine PR, Busquets O, Verdaguer E, Castro-Torres RD, García ML, Beas-Zarate C, Olloquequi J, Auladell C, Folch J, Camins A.

Mol Neurobiol. 2019 Dec 14. doi: 10.1007/s12035-019-01849-6. [Epub ahead of print]

PMID:
31838720
4.

c-Jun N-terminal Kinase 1 ablation protects against metabolic-induced hippocampal cognitive impairments.

Busquets O, Ettcheto M, Eritja À, Espinosa-Jiménez T, Verdaguer E, Olloquequi J, Beas-Zarate C, Castro-Torres RD, Casadesús G, Auladell C, Bulló M, Folch J, Camins A.

J Mol Med (Berl). 2019 Dec;97(12):1723-1733. doi: 10.1007/s00109-019-01856-z. Epub 2019 Dec 3.

PMID:
31797011
5.

The Involvement of Peripheral and Brain Insulin Resistance in Late Onset Alzheimer's Dementia.

Folch J, Olloquequi J, Ettcheto M, Busquets O, Sánchez-López E, Cano A, Espinosa-Jiménez T, García ML, Beas-Zarate C, Casadesús G, Bulló M, Auladell C, Camins A.

Front Aging Neurosci. 2019 Sep 6;11:236. doi: 10.3389/fnagi.2019.00236. eCollection 2019.

6.

Effects of MDMA on neuroplasticity, amyloid burden and phospho-tau expression in APPswe/PS1dE9 mice.

Abad S, Ramon-Duaso C, López-Arnau R, Folch J, Pubill D, Camarasa J, Camins A, Escubedo E.

J Psychopharmacol. 2019 Sep;33(9):1170-1182. doi: 10.1177/0269881119855987. Epub 2019 Jun 20.

PMID:
31219369
7.

Potential preventive disease-modifying pharmacological strategies to delay late onset Alzheimer's disease.

Ettcheto M, Busquets O, Camins A.

Neural Regen Res. 2019 Oct;14(10):1721-1725. doi: 10.4103/1673-5374.257513.

8.

Current Applications of Nanoemulsions in Cancer Therapeutics.

Sánchez-López E, Guerra M, Dias-Ferreira J, Lopez-Machado A, Ettcheto M, Cano A, Espina M, Camins A, Garcia ML, Souto EB.

Nanomaterials (Basel). 2019 May 31;9(6). pii: E821. doi: 10.3390/nano9060821. Review.

9.

A metabolic perspective of late onset Alzheimer's disease.

Ettcheto M, Cano A, Busquets O, Manzine PR, Sánchez-López E, Castro-Torres RD, Beas-Zarate C, Verdaguer E, García ML, Olloquequi J, Auladell C, Folch J, Camins A.

Pharmacol Res. 2019 Jul;145:104255. doi: 10.1016/j.phrs.2019.104255. Epub 2019 May 7. Review.

10.

Dual-drug loaded nanoparticles of Epigallocatechin-3-gallate (EGCG)/Ascorbic acid enhance therapeutic efficacy of EGCG in a APPswe/PS1dE9 Alzheimer's disease mice model.

Cano A, Ettcheto M, Chang JH, Barroso E, Espina M, Kühne BA, Barenys M, Auladell C, Folch J, Souto EB, Camins A, Turowski P, García ML.

J Control Release. 2019 May 10;301:62-75. doi: 10.1016/j.jconrel.2019.03.010. Epub 2019 Mar 13.

11.

ADAM10 in Alzheimer's disease: Pharmacological modulation by natural compounds and its role as a peripheral marker.

Manzine PR, Ettcheto M, Cano A, Busquets O, Marcello E, Pelucchi S, Di Luca M, Endres K, Olloquequi J, Camins A, Cominetti MR.

Biomed Pharmacother. 2019 May;113:108661. doi: 10.1016/j.biopha.2019.108661. Epub 2019 Mar 2. Review.

12.

Role of brain c-Jun N-terminal kinase 2 in the control of the insulin receptor and its relationship with cognitive performance in a high-fat diet pre-clinical model.

Busquets O, Eritja À, López BM, Ettcheto M, Manzine PR, Castro-Torres RD, Verdaguer E, Olloquequi J, Vázquez-Carrera M, Auladell C, Folch J, Camins A.

J Neurochem. 2019 Apr;149(2):255-268. doi: 10.1111/jnc.14682. Epub 2019 Mar 27.

PMID:
30734928
13.

JNK Isoforms Are Involved in the Control of Adult Hippocampal Neurogenesis in Mice, Both in Physiological Conditions and in an Experimental Model of Temporal Lobe Epilepsy.

Castro-Torres RD, Landa J, Rabaza M, Busquets O, Olloquequi J, Ettcheto M, Beas-Zarate C, Folch J, Camins A, Auladell C, Verdaguer E.

Mol Neurobiol. 2019 Aug;56(8):5856-5865. doi: 10.1007/s12035-019-1476-7. Epub 2019 Jan 26.

PMID:
30685843
14.

Triple GLP-1/GIP/glucagon receptor agonists, a potential novel treatment strategy in Alzheimer's disease.

Camins A, Ettcheto M, Busquets O, Manzine PR, Castro-Torres RD, Beas-Zarate C, Verdaguer E, Sureda FX, Bulló M, Olloquequi J, Auladell C, Folch J.

Expert Opin Investig Drugs. 2019 Jan;28(1):93-97. doi: 10.1080/13543784.2019.1552677. Epub 2018 Dec 1. No abstract available.

PMID:
30480461
15.

The Ethyl Acetate Extract of Leaves of Ugni molinae Turcz. Improves Neuropathological Hallmarks of Alzheimer's Disease in Female APPswe/PS1dE9 Mice Fed with a High Fat Diet.

Jara-Moreno D, Castro-Torres RD, Ettcheto M, Auladell C, Kogan MJ, Folch J, Verdaguer E, Cano A, Busquets O, Delporte C, Camins A.

J Alzheimers Dis. 2018;66(3):1175-1191. doi: 10.3233/JAD-180174.

PMID:
30400089
16.

Memantine loaded PLGA PEGylated nanoparticles for Alzheimer's disease: in vitro and in vivo characterization.

Sánchez-López E, Ettcheto M, Egea MA, Espina M, Cano A, Calpena AC, Camins A, Carmona N, Silva AM, Souto EB, García ML.

J Nanobiotechnology. 2018 Mar 27;16(1):32. doi: 10.1186/s12951-018-0356-z.

17.

Epigallocatechin-3-gallate loaded PEGylated-PLGA nanoparticles: A new anti-seizure strategy for temporal lobe epilepsy.

Cano A, Ettcheto M, Espina M, Auladell C, Calpena AC, Folch J, Barenys M, Sánchez-López E, Camins A, García ML.

Nanomedicine. 2018 Jun;14(4):1073-1085. doi: 10.1016/j.nano.2018.01.019. Epub 2018 Feb 15.

PMID:
29454994
18.

Excitotoxicity in the pathogenesis of neurological and psychiatric disorders: Therapeutic implications.

Olloquequi J, Cornejo-Córdova E, Verdaguer E, Soriano FX, Binvignat O, Auladell C, Camins A.

J Psychopharmacol. 2018 Mar;32(3):265-275. doi: 10.1177/0269881118754680. Epub 2018 Feb 15. Review.

PMID:
29444621
19.

Peripheral and Central Effects of Memantine in a Mixed Preclinical Mice Model of Obesity and Familial Alzheimer's Disease.

Ettcheto M, Sánchez-López E, Gómez-Mínguez Y, Cabrera H, Busquets O, Beas-Zarate C, García ML, Carro E, Casadesus G, Auladell C, Vázquez Carrera M, Folch J, Camins A.

Mol Neurobiol. 2018 Sep;55(9):7327-7339. doi: 10.1007/s12035-018-0868-4. Epub 2018 Feb 5.

PMID:
29404958
20.

Alpha-Secretase ADAM10 Regulation: Insights into Alzheimer's Disease Treatment.

Peron R, Vatanabe IP, Manzine PR, Camins A, Cominetti MR.

Pharmaceuticals (Basel). 2018 Jan 29;11(1). pii: E12. doi: 10.3390/ph11010012. Review.

Supplemental Content

Loading ...
Support Center